Instead, agents that disrupt the PGF/FLT1/AKT pathway, such as the pan-VEGFR inhibitor axitinib, are more likely to be effective at re-sensitizing PARPi-resistant breast cancers to PARPi. The gene discussed is FLT1; the disease is breast carcinoma.